Can positron emission tomography facilitate paediatric drug development?

Area of Science:

• Pharmacology
• Medical Imaging
• Paediatrics

Background:

• Paediatric drug development requires understanding growth's impact on drug disposition and action.
• There is a growing need for non-invasive methods for drug monitoring in children.

Purpose of the Study:

• To discuss the role of positron emission tomography (PET) in paediatric drug monitoring.
• To highlight PET's potential in paediatric drug development and evaluation.

Main Methods:

• Utilizing positron emission tomography (PET), a molecular imaging technique.
• Radiolabelling drugs with positron-emitting radionuclides to track their distribution.
• Directly assessing pharmacokinetic and pharmacodynamic events in human subjects.

Main Results:

• PET enables direct assessment of drug disposition and action in paediatric populations.
• This technique provides a novel perspective for paediatric drug research.
• PET can potentially contribute to drug development and evaluation processes in paediatrics.

Conclusions:

• Positron emission tomography (PET) is a valuable tool for non-invasive drug monitoring in children.
• PET offers unique insights into paediatric pharmacokinetics and pharmacodynamics.
• Ethical and methodological considerations are important for implementing PET in paediatric drug research.